GlassScriptPhysician profile
Hesham E Abdelrazek
NPI 1841266681
$1,737.66
in general payments reported to CMS, 2019-2025
21 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2022: $51.00 · 2023: $178 · 2024: $501 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.76 |
| Education | $178.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragonix Technologies, INC. | $265.54 | 2025 | Lungguard, Baroguard |
| Actelion Pharmaceuticals US, INC. | $237.29 | 2019-2025 | Uptravi, Opsumit |
| Astellas Pharma US INC | $199.25 | 2024-2025 | Cresemba |
| Abbvie INC. | $188.62 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.10 | 2023-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $112.55 | 2019-2025 | Prevymis, Zerbaxa, Keytruda |
| Intuitive Surgical, INC. | $90.32 | 2024 | |
| Pulmonx Corporation | $84.00 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.22 | 2019-2025 | Jascayd |
| Insmed, INC. | $71.64 | 2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $40.53 | 2019-2025 | Libtayo |
| Biomerieux INC | $32.58 | 2023 | Filmarray Pneumonia Panel (Pneumo) |
| Eurofins Viracor, LLC | $32.20 | 2019 | |
| Genzyme Corporation | $28.59 | 2025 | |
| Vifor Pharma, INC. | $24.15 | 2024 | Zemaira |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $23.72 | 2022 | |
| United Therapeutics Corporation | $22.01 | 2025 | Tyvaso |
| Invivyd INC | $21.28 | 2025 | Pemgarda |
| Verona Pharma, INC. | $20.83 | 2025 | Ohtuvayre |
| Philips North America LLC | $20.56 | 2025 | Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $16.68 | 2025 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesham Abdelrazek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.